Amylin Calls For Lilly Marketing Injunction In 9th Circ.

Law360, Los Angeles (October 11, 2011, 7:51 PM EDT) -- Amylin Pharmaceuticals Inc. told the Ninth Circuit on Tuesday that a lower court wrongly refused to block Eli Lilly & Co. from allegedly violating a joint marketing agreement by selling Amylin's diabetes drug alongside rival treatments made by Boehringer Ingelheim GmbH.

Amylin told a three-judge panel that Lilly sales representatives tasked with promoting Byetta, which treats type 2 diabetes, were instructed to pitch the medication to doctors as a secondary option behind Boehringer's Tradjenta.

The decision to relegate Amylin's medication violates the terms of the marketing...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.